SAN DIEGO, Oct. 26, 2016 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company
will report its third quarter 2016 results after the Nasdaq market
closes on Wednesday, November 2,
2016. Neurocrine will then host a live conference call
and webcast to discuss its financial results and provide a Company
update Wednesday afternoon, November 2,
2016 at 5:00 p.m. Eastern Time
(2:00 p.m. Pacific Time).
Participants can access the live conference call by dialing
888-632-3382 (US) or 785-424-1677 (International) using the
conference ID: NBIX. The call can also be accessed via the webcast
through the Company's website at http://www.neurocrine.com.
If you are unable to attend the webcast and would like further
information on this announcement please contact the Investor
Relations Department at Neurocrine Biosciences at (858) 617-7600.
A replay of the conference call will be available
approximately one hour after the conclusion of the call by dialing
800-839-2389 (US) or 402-220-7204 (International) using the
conference ID: NBIX. The call will be archived for one month.
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and INGREZZA, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement disorders.
Neurocrine intends to maintain certain commercial rights to its
VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-to-report-third-quarter-2016-results-300350229.html
SOURCE Neurocrine Biosciences, Inc.